Rabbit Polyclonal NT5E Antibody

NT5E (CD73), a cell surface ectoenzyme encoded by the NT5E gene, catalyzes the hydrolysis of extracellular adenosine monophosphate (AMP) to adenosine, a key immunosuppressive molecule. It plays a critical role in purinergic signaling, regulating immune responses and tissue homeostasis. Overexpression of NT5E is observed in various cancers, including melanoma, glioblastoma, and breast cancer, where it promotes tumor progression by suppressing antitumor immunity via adenosine-mediated inhibition of T cells and natural killer cells. Additionally, NT5E contributes to fibrosis, angiogenesis, and metastasis. NT5E-targeting antibodies have emerged as therapeutic tools to block its enzymatic activity or disrupt interactions with tumor microenvironments. Preclinical studies demonstrate that anti-NT5E antibodies enhance immune activation, reduce tumor growth, and synergize with checkpoint inhibitors like anti-PD-1/PD-L1 agents. Several NT5E antibody-based therapies (e.g., MEDI9447) are under clinical evaluation for cancer immunotherapy. Beyond therapeutics, NT5E antibodies are widely used in research to detect protein expression in tissues or cells via techniques like flow cytometry, immunohistochemistry, and Western blotting. Their development reflects the growing focus on targeting adenosine pathways to overcome immune evasion in cancer and inflammatory diseases.